A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Research and Clinical Trials Bookmark and Share

Research and Clinical Trials

City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute is recognized internationally for its breakthrough research discoveries and clinical trials for developing new ways to treat hematological cancers. Patients at City of Hope will have the ability to enroll in these trials, which can expand their treatment options and improve their outcomes. Learn more about our clinical trials program .
 
Highlights of our current research efforts include:

Reducing the Risk of GvHD
 
While stem cell transplants can be a lifesaving procedure for patients with hematologic disorders, it also carries a risk of graft versus host disease (GvHD), in which the newly transplanted stem cells do not recognize the recipient’s body as their own and start producing an immune response against it, leading to chronic and potentially serious complications. To reduce the likelihood of GvHD and to improve transplant outcomes, City of Hope is researching new ways to classify and match stem cell donors and recipients.
 
Adoptive T Cell Therapy
 
Harnessing the patient’s own immune system against the cancer, specifically through T-cell modification. In this experimental therapy, the patient’s own T-cells are extracted from the body, modified to recognize and attack cancer cells and re-infused back into the patient. This treatment has shown positive results for patients with lymphoma and lymphoid leukemia and is currently being studied for its potential against myeloid leukemia and multiple myeloma. Learn more about our Adoptive T Cell Therapy research.
 
Nonmyeloablative (Mini) Transplants
 
Our use and refinement of nonmyeloablative (“mini”) transplants, which relies less on the heavy doses of chemotherapy and radiation and more on the anti-cancer effects of the transplant itself. This novel approach allows otherwise ineligible patients, such as older patients or those who cannot tolerate radiation/chemotherapy-related effects, to be treated with this lifesaving procedure. Learn more about nonmyeloablative transplants.
 
Specialized Drug Studies
 
Continual development and improvement of drug regimens to treat hematologic cancers. Recently, City of Hope had led a national study of the drug brentuximab in patients with relapsed Hodgkin lymphoma, in whom the drug produced a high rate of response compared to standard therapy.
 
Leukemia Stem Cell Research
 
The Division of Stem Cell and Leukemia Research is currently investigating leukemia stem cells, which several studies have suggested to cause leukemia. By identifying and eradicating these cancerous stem cells — instead of just the mature leukemia cells that conventional therapies target — a definitive cure for this disease can be achieved.
 
Long-term Follow-up Program
 
City of Hope has a formal Long-term Follow-up Program that monitors all patients who have received a transplant at City of Hope to ensure they have optimal quality of life following their diagnoses and treatments. The program also helps researchers compile data on long-term outcomes to increase awareness of the kinds of problems, both physical and psychological, that some patients face after transplant, so patients can receive timely and appropriate information and care.
 
National Cancer Institute Project Grant
 
The City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute has been continuously funded for nearly 30 years by the National Cancer Institute (NCI) to develop innovative therapies for people battling leukemia, lymphoma and other cancers. The NCI grant supports continuing research aimed at improving the outcome for patients undergoing either autologous or allogeneic transplant for a hematologic cancer. The grant also allows researchers at City of Hope to develop laboratory-based clinical studies to expand the scope and applications of stem cell transplants. These studies include incorporating gene transfer, molecular biology, radioimmunotherapy, cellular immunotherapy and genetics to improve transplant outcomes.
 
SPORE Grant
 
City of Hope was awarded a Specialized Program of Research Excellence (SPORE) grant to further its work in utilizing transplant and non-transplant approaches for the treatment of lymphoma. This SPORE is one of only five lymphoma SPORE awards granted in the United States and builds upon the expertise in the transplant and cancer immunotherapy programs at City of Hope.
 
 
If you have been diagnosed with a hematologic cancer or are looking for a second opinion consultation about your treatment, find out more about becoming a patient or contact us at 800-826-HOPE.
 

Research and Clinical Trials

Research and Clinical Trials

City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute is recognized internationally for its breakthrough research discoveries and clinical trials for developing new ways to treat hematological cancers. Patients at City of Hope will have the ability to enroll in these trials, which can expand their treatment options and improve their outcomes. Learn more about our clinical trials program .
 
Highlights of our current research efforts include:

Reducing the Risk of GvHD
 
While stem cell transplants can be a lifesaving procedure for patients with hematologic disorders, it also carries a risk of graft versus host disease (GvHD), in which the newly transplanted stem cells do not recognize the recipient’s body as their own and start producing an immune response against it, leading to chronic and potentially serious complications. To reduce the likelihood of GvHD and to improve transplant outcomes, City of Hope is researching new ways to classify and match stem cell donors and recipients.
 
Adoptive T Cell Therapy
 
Harnessing the patient’s own immune system against the cancer, specifically through T-cell modification. In this experimental therapy, the patient’s own T-cells are extracted from the body, modified to recognize and attack cancer cells and re-infused back into the patient. This treatment has shown positive results for patients with lymphoma and lymphoid leukemia and is currently being studied for its potential against myeloid leukemia and multiple myeloma. Learn more about our Adoptive T Cell Therapy research.
 
Nonmyeloablative (Mini) Transplants
 
Our use and refinement of nonmyeloablative (“mini”) transplants, which relies less on the heavy doses of chemotherapy and radiation and more on the anti-cancer effects of the transplant itself. This novel approach allows otherwise ineligible patients, such as older patients or those who cannot tolerate radiation/chemotherapy-related effects, to be treated with this lifesaving procedure. Learn more about nonmyeloablative transplants.
 
Specialized Drug Studies
 
Continual development and improvement of drug regimens to treat hematologic cancers. Recently, City of Hope had led a national study of the drug brentuximab in patients with relapsed Hodgkin lymphoma, in whom the drug produced a high rate of response compared to standard therapy.
 
Leukemia Stem Cell Research
 
The Division of Stem Cell and Leukemia Research is currently investigating leukemia stem cells, which several studies have suggested to cause leukemia. By identifying and eradicating these cancerous stem cells — instead of just the mature leukemia cells that conventional therapies target — a definitive cure for this disease can be achieved.
 
Long-term Follow-up Program
 
City of Hope has a formal Long-term Follow-up Program that monitors all patients who have received a transplant at City of Hope to ensure they have optimal quality of life following their diagnoses and treatments. The program also helps researchers compile data on long-term outcomes to increase awareness of the kinds of problems, both physical and psychological, that some patients face after transplant, so patients can receive timely and appropriate information and care.
 
National Cancer Institute Project Grant
 
The City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute has been continuously funded for nearly 30 years by the National Cancer Institute (NCI) to develop innovative therapies for people battling leukemia, lymphoma and other cancers. The NCI grant supports continuing research aimed at improving the outcome for patients undergoing either autologous or allogeneic transplant for a hematologic cancer. The grant also allows researchers at City of Hope to develop laboratory-based clinical studies to expand the scope and applications of stem cell transplants. These studies include incorporating gene transfer, molecular biology, radioimmunotherapy, cellular immunotherapy and genetics to improve transplant outcomes.
 
SPORE Grant
 
City of Hope was awarded a Specialized Program of Research Excellence (SPORE) grant to further its work in utilizing transplant and non-transplant approaches for the treatment of lymphoma. This SPORE is one of only five lymphoma SPORE awards granted in the United States and builds upon the expertise in the transplant and cancer immunotherapy programs at City of Hope.
 
 
If you have been diagnosed with a hematologic cancer or are looking for a second opinion consultation about your treatment, find out more about becoming a patient or contact us at 800-826-HOPE.
 
Quick Links
About the HCT Program
Stephen J. Forman, M.D., chair of hematology and hematopoietic cell transplantation, shares his views on the essence of care at City of Hope. He highlights the bone marrow transplant program (BMT) and the program's growth over the years.
 
Other videos:
 
 
How to Become a Cure

 
What is a blood stem cell transplant? A remarkably effective treatment for leukemia, lymphoma, multiple myeloma - and many other diseases of the blood and bone marrow. This video shows the fascinating and dramatic journey of a blood stem cell donation all the way from a donor to a patient in need. Find out how you can become a bone marrow or stem cell donor »
Past BMT Reunions
Each year, City of Hope invites bone marrow transplant recipients and their families to attend the "Celebration of Life" event. View highlights from past reunions.
 
The focus of the Division of Hematopoietic Stem Cell and Leukemia Research is to improve the understanding of leukemia stem cells in order to develop cures for leukemia and other hematologic malignancies.
City of Hope's partnership with the Los Angeles Dodgers, includes ThinkCure!, an innovative, community-based non-profit that raises funds to accelerate collaborative research at City of Hope and Childrens Hospital Los Angeles to cure cancers.
 


NEWS & UPDATES
  • To say that myelofibrosis patients need more treatment options would be an understatement. The severely low platelet counts, known as thrombocytopenia, that are one of the hallmark symptoms of the disease can lead to chronic fatigue and weakness that not only damage quality of life but, ultimately, shorten life...
  • Patients with metastatic colorectal cancer often stop responding to the primary drugs used against the disease, leaving them with few options and little hope. Determined to increase those options, doctors and researchers at City of Hope are conducting two clinical trials that could lead to new treatments for pe...
  • Investigators working at City of Hope are making many significant inroads against many forms of cancer. To do that, they have to take a variety of approaches. Molecular oncology researchers focus on abnormal cancer-associated activity in a cell’s nucleus. One especially prominent factor in many breast and ovari...
  • In light of the new breast cancer screening guidelines, which call for women to have mammograms every other year from age 50 to 74, it’s more important than ever for women to understand their individual risk. On Monday, the U.S. Preventive Services Task force released new breast cancer screening guideline...
  • Cancer patients need, and deserve, more than medical care. They and their families need high-quality supportive care – that is, care that addresses their physical, emotional and spiritual well-being. Health care professionals increasingly understand this, but starting such programs from scratch isn’t easy...
  • Each year, City of Hope patients given another chance at life gather to pose for a picture like this one. Going on its 39th year, the celebration of patients free of blood cancers thanks to bone marrow or stem cell transplants has grown such that a photographer has to scale a cherry picker just to […]
  • Cancer patients who are participating in early-stage clinical trials need extra emotional and physical support due to their additional stress and often unique symptoms. Now an effort by researchers at City of Hope to create a model for such support has received a $6.8 million grant from the National Cancer Inst...
  • The need for improvements in treating malignant brain tumors has never been greater. Survival for many patients with these tumors are sometimes measured in just months. One reason that therapeutic options are limited is that traditional surgery is deemed too risky for many brain tumors, especially for those in ...
  • “Honestly, there’s nothing special about my story,” protested Daniel Samson, as he bounced Layla, his 3 1/2-year-old daughter, on his lap and put on a video for her to watch. “I just want to tell it for my own sake, and share it with other men who may be going through this chaos.” Samson spoke […]
  • As far back as he can remember, Jonathan Yamzon, M.D., wanted to be a doctor. “I knew it from the get-go,” he said, matter-of-factly. “I always envisioned it as the ideal; the supreme thing one could do with one’s life.” The youngest of six children, Yamzon was barely a toddler when his family moved to [&...
  • There’s never a “good” time for cancer to strike. With testicular cancer, the timing can seem particularly unfair. This disease targets young adults in the prime of life; otherwise healthy people unaccustomed to any serious illness, let alone cancer. And suddenly … “I can only imagine what they must...
  • Sure, a healthy lifestyle can lower a person’s risk, but the impact of specific actions is harder to tease out. Diet, exercise, tobacco use, nutritional supplements, alcohol consumption … How important are each of these factors, individually? Does strict adherence to (or rejection of) one get you a pass o...
  • Health care decisions are tough. They’re even tougher when you – or loved ones – have to make them without a plan or a conversation. National Healthcare Decisions Day, on April 16,  is a nationwide initiative to demystify the health care decision-making process and encourage families to start talking. Ult...
  • The statistics, direct from the American Cancer Society, are sobering: Cancer death rates among African-American men are 27 percent higher than for white men. The death rate for African-American women is 11 percent higher compared to white women. Hispanics have higher rates of cervical, liver and stomach cancer...
  • “Lucky” is not usually a term used to describe someone diagnosed with cancer.  But that’s how 34-year-old Alex Camargo’s doctor described him when he was diagnosed with thyroid cancer — the disease is one of the most treatable cancers at all stages. That doctor was ultimately proved righ...